ASCO

GSK Oncology Pipeline: Showcasing Long-Term Outcomes at ASCO and EHA 2026

By BiotechReality Business Intelligence Desk
26 May 2026

GSK is set to demonstrate the strength of its oncology pipeline at major 2026 congresses, highlighting long-term outcomes for Jemperli and Blenrep alongside new GIST data.

Tag: ASCO

GSK Oncology Pipeline: Showcasing Long-Term Outcomes at ASCO and EHA 2026

Areas Covered

Discover More

AstraZeneca’s Enhertu EU Approval: Enhertu Plus Pertuzumab Cleared as First-Line Therapy for HER2-Positive Metastatic Breast Cancer

Lilly Merida Biosciences Acquisition: Eli Lilly to Pay $2.875 Billion for Precision Autoantibody Therapies

Roche Vabysmo PCV Study Shows Sustained Two-Year Results in Difficult-to-Treat nAMD Subtype

TEZSPIRE Eosinophilic Esophagitis Trial: Amgen, AstraZeneca Report Positive Phase 3 CROSSING Results

Abbott Libre Duo 10 Day Wins FDA Authorization as World’s First Dual Glucose-Ketone Sensor

Johnson & Johnson’s IMAAVY Nipocalimab-aahu Wins FDA Approval as First-Ever Treatment for Warm Autoimmune Hemolytic Anemia